Targeting Piezo1 unleashes innate immunity against cancer and infectious disease
Berk Aykut(Duke University), George Miller(University of North Carolina at Chapel Hill), Deepak Saxena(New York University), Joshua Leinwand(Icahn School of Medicine at Mount Sinai), Smruti Pushalkar(New York University), Pamela Preiss(New York University), Matthew E. Berman(New York University), Gregor Werba(NYU Langone Health), Sorin A. A. Shadaloey(New York University), Steve Ki Buom Lee(New York University), Anjana Saxena(The Graduate Center, CUNY), Dongling Wu(New York University), William A. Coetzee(New York University), Alireza Khodadadi‐Jamayran(NYU Langone Health), Wei Wang(Capital Medical University), Ruonan Chen(Simcere Pharmaceutical (China)), Jacqueline I. Kim(Miami Transplant Institute), Brian Diskin(New York University), Raquel Abengozar(New York University)
Cited by 151
Related Papers
Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment
|Nature Genetics|2022|527
Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment
|Nature Communications|2023|265
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma
|The Journal of Experimental Medicine|2017|239
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans
|Journal of Clinical Investigation|2012|207